Latest news
Iconovo signs an agreement with Stevanato Group regarding the manufacture, sale and distribution of ICOcap
The inhalation developer Iconovo AB (publ) announced today that the company has signed an agreement with the multinational Stevanato Group, headquartered…
Dr Orest Lastow is lecturing at Dry Powder Inhalers Annual Conference London 20-21 June 2018
The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great…
Press releases
Nov 30, 2023, 09:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Nov 30, 2023, 09:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Nov 29, 2023, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 29, 2023, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 16, 2023, 11:15
News
IR
English
Corporate Action
Other
Nov 16, 2023, 11:15
News
IR
Swedish
Corporate Action
Other
Oct 31, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Oct 27, 2023, 14:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Oct 27, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Oct 17, 2023, 21:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
mfn-cus-disclaimer
Sep 26, 2023, 23:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Sep 26, 2023, 23:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 23:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 09:15
News
IR
Swedish
Corporate Action
Other
Sep 26, 2023, 09:15
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
English
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
